Date | Title | Description | |
---|---|---|---|
21 Feb 2023 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
23 Nov 2022 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day | Download |
04 Nov 2022 | On business and financial situation | The Company releases the press release related to the first nine months of 2022 financial results | Download |
04 Nov 2022 | On business and financial situation | The Company releases the first nine months 2022 financial results presentation | Download |
15 Mar 2022 | On significant placements in financial instruments | Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
10 Apr 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2023 | Download |
21 Feb 2023 | Annual Corporate Governance Report | ROVI releases the 2022 Annual Corporate Governance Report | Download |
21 Feb 2023 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors | Download |
16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |
09 Jan 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2022 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |